Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].","authors":"H Zhang, X Y He, X Xiao, H R Lyu, M F Zhao","doi":"10.3760/cma.j.cn121090-20251219-00604","DOIUrl":"10.3760/cma.j.cn121090-20251219-00604","url":null,"abstract":"<p><p>To evaluate the efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after failure of chimeric antigen receptor T (CAR-T) cell therapy. Nine patients with R/R DLBCL who failed CAR-T therapy and received glofitamab combined with polatuzumab vedotin treatment at the Hematology Department of Tianjin First Central Hospital from March 2024 to April 2025 were selected for retrospective analysis of their clinical data. The overall response rate was 77.8%, and the complete response rate was 55.6% following six cycles of treatment. The median follow-up period was 12 (5-18) months. The 1-year progression-free survival rate and overall survival rate were 71.1% (95% <i>CI</i>: 56.3%-86.1%) and 76.2% (95% <i>CI</i>: 64.0%-94.2%), respectively. All 9 patients experienced cytokine release syndrome, with 7 cases at grade 1-2 and 2 cases at grade 3. One patient had grade 1 immune effector cell-associated neurotoxicity syndrome. Glofitamab combined with polatuzumab vedotin shows preliminary efficacy and a manageable safety in patients with R/R DLBCL after CAR-T cell therapy failure.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"704-707"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety analysis of the salvage treatment for diffuse large B-cell lymphoma after the failure of anti-CD19 CAR-T therapy].","authors":"Y Lu, L L Zhou, S G Ye, C Y Yao, B T Wang, A B Liang, P Li","doi":"10.3760/cma.j.cn121090-20260413-00193","DOIUrl":"10.3760/cma.j.cn121090-20260413-00193","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the efficacy and safety of the salvage treatment in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who failed prior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy. <b>Methods:</b> This study retrospectively analyzed clinical data of 23 patients with DLBCL who failed CD19 CAR-T therapy at the Department of Hematology, Tongji Hospital, from March 2022 to March 2026. Patients were divided into the anti-CD20 T-cell immunotherapy group (<i>n</i>=12) and non-anti-CD20 T-cell immunotherapy group (<i>n</i>=11). Efficacy and safety were compared between the two groups. <b>Results:</b> This study included 23 patients. With a median follow-up of 13.5 (95% <i>CI</i>: 10.4-31.9) months, the overall response rate (ORR) was 60.8% (14/23), and 11 (47.8%) patients achieved complete remission (CR). Median progression-free survival (PFS) and overall survival (OS) were not reached. In the anti-CD20 T-cell immunotherapy group, ORR was 100% with a CR rate of 91.7%, and the median PFS and OS were not reached. In the non-anti-CD20 T-cell immunotherapy group, ORR was 18.2% (95% <i>CI</i>: 2.3%-51.8%) with only two partial responses, and the median PFS and OS were 1.7 and 2.6 months, respectively (<i>P</i><0.001 for both). Regarding safety, 10 (83.3%) patients in the T-cell immunotherapy group developed grade 1-2 cytokine release syndrome, and no immune effector cell-associated neurotoxicity syndrome occurred. In the non-anti-CD20 T-cell immunotherapy group, the main adverse events were hematologic toxicities. <b>Conclusion:</b> Anti-CD20 T-cell immunotherapy yields significantly higher response rates and longer survival compared with non-anti-CD20 T-cell immunotherapy in patients with DLBCL failing anti-CD19 CAR-T therapy, with a manageable safety profile.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"641-648"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of ivosidenib-based therapy in 16 patients with IDH1-mutated acute myeloid leukemia].","authors":"D D Chen, J C Xu, Z Yin, P C Shi, D Xu, J Y Ye, H Liu, L Xuan, Y Zhang, Q F Liu, G P Yu","doi":"10.3760/cma.j.cn121090-20251125-00546","DOIUrl":"10.3760/cma.j.cn121090-20251125-00546","url":null,"abstract":"<p><p>To evaluate the real-world application of ivosidenib (IVO) in patients with IDH1-mutated acute myeloid leukemia (AML), as well as its efficacy and safety. We retrospectively analyzed clinical data from 16 patients with IDH1-mutated AML who received IVO-based therapy at Nanfang Hospital between September 2021 and May 2025. The median age was 57 years (range, 25 - 80 years), with 7 males and 9 females. Six patients (37.5%) had an Eastern Cooperative Oncology Group performance status of 3 - 4, and 14 patients (87.5%) were classified as intermediate- or high-risk according to the European LeukemiaNet criteria. Among 5 patients (31.2%) receiving venetoclax (VEN) plus azacitidine (AZA) combined with IVO for induction, 3 achieved complete remission (CR), including 2 with measurable residual disease (MRD) -negative and IDH1 dPCR-negative status. Two patients (12.5%) received VA plus IVO for consolidation; both maintained CR, with 1 achieving MRD-negative and IDH1 dPCR-negative status. Four relapsed or refractory patients (25.0%) received VEN plus hypomethylating agents (HMA) combined with IVO (<i>n</i>=3) or IVO alone (<i>n</i>=1) for salvage therapy. All patients achieved CR, of whom 3 obtained MRD-negative results, and 1 was IDH1 dPCR-negative. Five patients (31.2%) received IVO as maintenance therapy, with a duration of response exceeding 12 months. The most common grade ≥3 adverse events were neutropenia (56.3%), anemia (43.8%), and thrombocytopenia (37.5%). IVO-related adverse events included differentiation syndrome (12.5%) and QT interval prolongation (12.5%), and no treatment-related deaths were observed. IVO-based regimens demonstrated favorable efficacy and a manageable safety profile across all treatment phases in patients with IDH1-mutated AML, supporting their broader clinical application.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"694-698"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Predictive value of next-generation sequencing-based measurable residual disease quantitative stratification for early disease progression in newly diagnosed multiple myeloma after induction therapy].","authors":"Y H Peng, X Zhou, S Yan, L Yao, D P Wu, C C Fu","doi":"10.3760/cma.j.cn121090-20260403-00173","DOIUrl":"10.3760/cma.j.cn121090-20260403-00173","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the predictive value of next-generation sequencing (NGS) -based quantitative minimal residual disease (MRD) stratification for early disease progression in patients newly diagnosed with multiple myeloma (NDMM) after induction therapy. &lt;b&gt;Methods:&lt;/b&gt; This retrospective cohort study analyzed the clinical data of 408 patients with NDMM admitted to the Department of Hematology, the First Affiliated Hospital of Soochow University between 2019 and 2024, who received the bortezomib + lenalidomide + dexamethasone (VRD) regimen induction therapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT). Bone marrow samples were collected after 4 cycles of induction therapy and before auto-HSCT, and MRD was detected by NGS technology with a sensitivity of 10-6. Patients were divided into the ultra-deep negative group (&lt;10(-6)), low-load positive group (≥10(-6) and ≤10(-3)), and high-load residual group (&gt;10(-3)) according to MRD burden, and the clinical characteristics and prognosis of each group were compared. &lt;b&gt;Results:&lt;/b&gt; After cycles of VRD induction therapy, the overall response rate was 96.8% (395/408), and 197 patients (48.3%) achieved complete remission or better. The positive rates of del (17p) were 4.4%, 15.5%, and 10.8%, respectively (&lt;i&gt;P&lt;/i&gt;=0.030) and the positive rates of t (4;14) were 13.3%, 19.0%, and 28.4% (&lt;i&gt;P&lt;/i&gt;=0.021) in the ultra-deep negative group (90 patients), low-load positive group (142 patients), and high-load residual group (176 patients), respectively, with the highest rate observed in the high-load residual group. The risk of disease progression in the ultra-deep negative group was reduced by 86% compared with the high-load residual group (&lt;i&gt;HR&lt;/i&gt;=0.14, 95%&lt;i&gt;CI&lt;/i&gt;: 0.08 - 0.26, &lt;i&gt;P&lt;/i&gt;&lt;0.001). The 24-month cumulative incidence of progression (CIF) in the ultra-deep negative group, low-load positive group, and high-load residual group was 1.2% (95% &lt;i&gt;CI&lt;/i&gt;: 0.1% - 5.9%), 8.3% (95% &lt;i&gt;CI&lt;/i&gt;: 4.4% - 13.9%), and 23.2% (95% &lt;i&gt;CI&lt;/i&gt;: 17.2% - 29.7%), respectively. Using the high-load residual group as reference, the risk of disease progression was significantly reduced in both the ultra-deep negative group (&lt;i&gt;sHR&lt;/i&gt; = 0.15, 95% &lt;i&gt;CI&lt;/i&gt;: 0.08 - 0.31) and the low-load positive group (&lt;i&gt;sHR&lt;/i&gt;=0.33, 95% &lt;i&gt;CI&lt;/i&gt;: 0.22 - 0.50) (both &lt;i&gt;P&lt;/i&gt;&lt;0.001). The risk of disease progression in the ultra-deep negative group was also significantly lower than that in the low-load positive group (sHR=0.48, 95% &lt;i&gt;CI&lt;/i&gt;: 0.24 - 0.94, &lt;i&gt;P&lt;/i&gt;=0.032). Multivariate analysis revealed that the MRD level was an independent prognostic factor, and the risk of disease progression in the high-load residual group was significantly higher than that in the ultra-deep negative group (&lt;i&gt;sHR&lt;/i&gt;=6.65, 95% &lt;i&gt;CI&lt;/i&gt;: 3.58 - 12.33, &lt;i&gt;P&lt;/i&gt;&lt;0.001) . &lt;b&gt;Conclusion:&lt;/b&gt; NGS-based quantitative MRD stratification has independent predictive value for early disease progression in patients with N","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"667-675"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575529/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of recipient age on outcomes of allogeneic hematopoietic stem cell transplantation: an analysis from the Chinese Bone Marrow Transplant Registry Group (CBMTRG)].","authors":"X L Liang, J Liu, L Xuan, Y Sun, J Chen, J Liu, H X Fu, C C Wang, S Y Lu, L P Xu, X Q Wang, R H Huang, D P Wu, D H Liu, Q F Liu, X Zhang, X J Huang","doi":"10.3760/cma.j.cn121090-20260324-00150","DOIUrl":"10.3760/cma.j.cn121090-20260324-00150","url":null,"abstract":"<p><p><b>Objective:</b> To investigate whether recipient age independently affects outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT), including the predominant patterns of treatment failure, after adjustment for confounding factors. <b>Methods:</b> This retrospective, multicenter cohort study included 1 619 patients who underwent a single allo-HSCT at five transplant centers from January 1 2018, to December 31 2023. Patients were categorized into younger (≤35 years) or older recipient groups (≥50 years). After propensity score matching to balance 11 covariates, the analysis included 694 patients (347 in each group). Overall survival (OS), non-relapse mortality (NRM), cumulative incidence of relapse (CIR), and cumulative incidence of acute and chronic graft-versus-host disease (aGVHD and cGVHD) were compared between the groups. <b>Results:</b> The median follow-up was 33.4 months (95% <i>CI</i>: 31.2 - 36.1 months). The 3-year OS rate was significantly lower in older than in younger recipients (75.5% ± 2.5% <i>vs</i> 83.1% ± 2.2%, <i>HR</i>=1.59, <i>P</i>=0.007). The 3-year NRM was higher in older recipients [13.3% ± 1.9% <i>vs</i> 8.5% ± 1.6%, univariable subdistribution <i>HR</i> (<i>SHR</i>) =1.61, <i>P</i>=0.044]. This association did not reach conventional statistical significance after multivariable adjustment (adjusted <i>SHR</i>=1.59, 95% <i>CI</i>: 0.99 - 2.54, <i>P</i>=0.053) ; however, the stable effect estimate indicated clinical relevance. No statistically significant between-group differences were observed in CIR or in the cumulative incidences of grade Ⅱ-Ⅳ aGVHD and cGVHD. Infection was the leading cause of NRM in both groups, whereas the proportions of deaths attributable to organ dysfunction and bleeding were higher among older recipients. <b>Conclusion:</b> After propensity score matching, older recipient age remained independently associated with poorer OS. This unfavorable outcome was primarily characterized by an increased risk of NRM, rather than that of relapse.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"626-634"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Germline DDX41 mutations and myelodysplastic neoplasms].","authors":"Y Zhong, Z J Xiao","doi":"10.3760/cma.j.cn121090-20251118-00537","DOIUrl":"10.3760/cma.j.cn121090-20251118-00537","url":null,"abstract":"<p><p>DDX41 mutations represent one of the most frequent germline mutations in patients with myelodysplastic neoplasms, conferring unique clinical features of age of onset, prognosis, pathogenic mechanisms, and treatment response. This review summarizes the molecular epidemiology and clinical features of germline DDX41-mutated MDS, with a particular focus on recent advances in the \"second-hit\" model underlying disease pathogenesis. We further review the efficacy of current therapeutic strategies and discuss the applicability and limitations of existing prognostic scoring systems for this unique patient population. This review aims to provide an updated overview of current evidence and to inform risk stratification, clinical management, and long-term care of patients with germline DDX41-mutated MDS.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"709-713"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of oral melphalan as conditioning regimen for autologous hematopoietic stem cell transplantation in multiple myeloma].","authors":"J Wang, L Gong, M M Pan, S W Jin, J Q Mi, W P Zhang, J Xu","doi":"10.3760/cma.j.cn121090-20260126-00060","DOIUrl":"10.3760/cma.j.cn121090-20260126-00060","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the safety and efficacy of oral melphalan as a conditioning regimen for patients with multiple myeloma (MM) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) . &lt;b&gt;Methods:&lt;/b&gt; This retrospective cohort study collected clinical data of patients with MM who underwent auto-HSCT at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from July 2022 to October 2023. Patients were divided into oral and intravenous groups according to the administration route of melphalan. Engraftment time (ET), overall responses, long-term outcomes, and melphalan-associated toxicities were assessed. The pharmacokinetics of melphalan were detected using a mass spectrometer. &lt;b&gt;Results:&lt;/b&gt; This study included 48 patients with MM who met the inclusion and exclusion criteria. Of these patients, 12 received tablet melphalan and 36 had the injection formulation. Upon engraft infusion, time to the lowest level (TTLL) and ET of neutrophils in the oral group were significantly longer than those in the injection group[TTLL: median, 9.0 (7.0-13.0) d &lt;i&gt;vs&lt;/i&gt; 7.0 (5.0-12.0) d, &lt;i&gt;P&lt;/i&gt;&lt;0.001; ET: median, 12.0 (10.0-14.0) d &lt;i&gt;vs&lt;/i&gt; 11.0 (9.0-12.0) d, &lt;i&gt;P&lt;/i&gt;&lt;0.001]. Such a lag also happened to the TTLL and ET of platelets in the oral group compared with the injection group[TTLL: median 10.0 (9.0-15.0) d &lt;i&gt;vs&lt;/i&gt; 9.0 (6.0-13.0) d, &lt;i&gt;P&lt;/i&gt;=0.004; ET: median, 14.5 (11.0-17.0) d &lt;i&gt;vs&lt;/i&gt; 12.0 (9.0-19.0) d, &lt;i&gt;P&lt;/i&gt;=0.002]. The lowest level of neutrophils in the oral group was higher than that in the injection group (0.11×10(9)/L &lt;i&gt;vs&lt;/i&gt; 0.02×10(9)/L, &lt;i&gt;P&lt;/i&gt;&lt;0.001), whereas the lowest level of platelets in both groups had no statistical difference (&lt;i&gt;P&lt;/i&gt;&gt;0.05). The median duration of neutropenia (&lt;0.5×10(9)/L) was comparable between the two groups. Regarding non-hematological side effects, patients who took melphalan orally had a remarkably lower frequency of gastrointestinal toxicities as opposed to those given intravenously (nausea: 50.0% &lt;i&gt;vs&lt;/i&gt; 100.0%, &lt;i&gt;P&lt;/i&gt;&lt;0.001; vomiting: 8.3% &lt;i&gt;vs&lt;/i&gt; 69.5%, &lt;i&gt;P&lt;/i&gt;=0.001; diarrhea: 50.0% &lt;i&gt;vs&lt;/i&gt; 83.3%, &lt;i&gt;P&lt;/i&gt;=0.030). The incidence of oral mucositis and liver or kidney impairments did not differ between the two groups. Post-auto-HSCT efficacy evaluation demonstrated no differences in the percentages of patients obtaining a very good partial response and better outcomes, as well as in the improvement rate to complete remission. With a median follow-up time of 37.9 (31.0 - 49.4) months, the median progression-free survival (PFS) of the oral and injection groups was not reached and 35.9 months (95% &lt;i&gt;CI&lt;/i&gt;: 28.3 months-not reached), respectively. Median overall survival (OS) was not reached for either. Neither PFS nor OS reached statistical significance between the two groups. To examine the drug bioavailability, melphalan pharmacokinetics were tested in 6 patients, comprising 3 from the oral group and 3 from the injection group. ","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"676-683"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical analysis of bendamustine combined with rituximab as first-line therapy for B-cell lymphoproliferative disorders other than follicular lymphoma].","authors":"X R Mi, W J Xiong, Y T Yan, T Y Wang, G An, D H Zou, Y Xu, W Liu, L G Qiu, R Lyu, S H Yi","doi":"10.3760/cma.j.cn121090-20260226-00109","DOIUrl":"10.3760/cma.j.cn121090-20260226-00109","url":null,"abstract":"<p><p>This study aimed to evaluate the efficacy and safety of bendamustine combined with rituximab as first-line therapy in B-cell lymphoproliferative disorders (BLPD) other than follicular lymphoma (FL). Based on the Lymphoma Subcohort of the National Hematological Disease Cohort Study, a total of 91 newly diagnosed patients with non-FL BLPD receiving frontline bendamustine-rituximab regimen at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences from August 2019 to February 2025 were enrolled.The median age of the cohort was 59 years (range, 30 - 79 years), with a male-to-female ratio of 1.6:1 (56 males and 35 females). Among all subjects, 78 patients completed ≥ 2 cycles of induction therapy, with a best complete response (CR) rate of 59.0% and an objective response rate of 88.5%. The primary grade 3 - 4 hematological adverse events included neutropenia, lymphopenia, anemia and thrombocytopenia, while common non-hematological adverse events consisted of fever, infection and abnormal liver function. With a median follow-up duration of 41 months (range, 2 - 70 months), the 5-year progression-free survival (PFS) rate and 5-year overall survival (OS) rate were 78.1% (95% <i>CI</i>:50.3%-91.5%) and 85.2% (95% <i>CI</i>:56.8%-95.6%), respectively. Multivariate analysis identified age ≥60 years as an independent risk factor for PFS (<i>HR</i>=9.161, 95% <i>CI</i>: 1.063-78.960, <i>P</i>=0.044), and CR achievement as an independent protective factor for PFS (<i>HR</i>=0.087, 95% <i>CI</i>: 0.009-0.807, <i>P</i>=0.032). In conclusion, bendamustine combined with rituximab is an effective first-line treatment option for patients with non-FL BLPD.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"699-703"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Inter-laboratory comparison of international standardized BCR::ABL1 (P210) mRNA of chronic myeloid leukemia patients by digital PCR].","authors":"Y Z Qin, D X Ma, Y Yao, Y M Zhu, Y L Zhang, H Liu, Y J Tang, S X Geng, C Qiao, C L Wang, M L Zhang, J H Zhang, L Yao, X Q Li, J F Zhou, Q Jiang","doi":"10.3760/cma.j.cn121090-20260123-00054","DOIUrl":"10.3760/cma.j.cn121090-20260123-00054","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the capability of digital PCR (dPCR) in detecting the internationally standardized BCR::ABL1 (P210) mRNA (BCR::ABL1(IS)) of patients with chronic myeloid leukemia through inter-laboratory sample distribution and comparison. <b>Methods:</b> This was a multi-center compatative trial study. A total of 37 samples with different BCR::ABL1(IS) levels were uniformly prepared from patient bone marrow or peripheral blood to be discarded for comparison. Among them, 22 samples were used for real-time reverse transcription quantitative PCR (RQ-PCR) detection to revalidate the conversion factor (CF), whereas another 15 samples, along with 6 samples used in RQ-PCR, were used for dPCR comparison. Peking University People's Hospital determined the validity of its own dPCR and RQ-PCR CFs by detecting World Health Organization international standards. Bland-Altman analysis was conducted to validate the CFs of participating laboratories. If no validated CF was available, the new CF was calculated using the current comparison samples, and its validity was assessed. <b>Results:</b> Among the 14 laboratories participating in the dPCR comparison, 13 detected BCR::ABL1 in all samples. Among the 13 laboratories participating in the RQ-PCR comparison, 5 had validated CFs, whereas the other 8 had validated CFs after recalculating. In the dPCR comparison, 11 laboratories used the same commercial kit, and 10 of them were qualified. Further, 1 laboratory used a laboratory-developed testing reagent and obtained a CF using the standard sample from the National Clinical Laboratory Center, which was also qualified, whereas the 2 laboratories with no CFs both had qualified CFs after calculating. Comparison of results from samples simultaneously performing dPCR and RQ-PCR demonstrated that the BCR::ABL1(IS) results derived from their respective qualified CFs showed no significant difference for each laboratory (all <i>P</i>≥0.1). However, among the 6 laboratories with unqualified original CFs in RQ-PCR, 2 showed significant differences between dPCR results and RQ-PCR results derived from the original CFs (<i>P</i><0.05), and 3 demonstrated tendencies toward significant differences (<i>P</i>>0.05 to <0.1) . <b>Conclusion:</b> dPCR detection of BCR::ABL1(IS) shows high sensitivity and accuracy and has high consistency with RQ-PCR results.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"635-640"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Effect of inorganic pyrophosphatase PPA1 on proliferation and apoptosis of abnormal naive cells in acute B-lymphocytic leukemia].","authors":"C X Hu, X H Zhang, X J Wang, J J Dai, F Zhang, X D Wei, X D Lyu","doi":"10.3760/cma.j.cn121090-20251103-00499","DOIUrl":"10.3760/cma.j.cn121090-20251103-00499","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the role of inorganic pyrophosphatase (PPA1) in the proliferation of abnormal naive lymphocytes in B-cell acute lymphoblastic leukemia (B-ALL) and evaluate its potential as a tumor marker. &lt;b&gt;Methods:&lt;/b&gt; Bioinformatics analysis predicted the characteristics of the PPA1 gene. Bone marrow specimens were collected from patients with B-ALL, and abnormal immature B lymphocytes were isolated by CD19 and CD10 immunomagnetic beads, with normal cells as controls. PPA1 expression was detected with quantitative polymerase chain reaction (qPCR) and Western blot. B-ALL cell lines NALM-6 and HAL-01 were cultured &lt;i&gt;in vitro&lt;/i&gt;, and recombinant PPA1 protein (rPPA1) or PPA1 monoclonal antibody was added to assess changes in cell proliferation, apoptosis, mitochondrial membrane potential, and cell cycle. The GV492-PPA1 overexpression plasmid was constructed and transfected into cells to assess the effect of PPA1 overexpression. shRNA was designed to construct the GV644-shPPA1 recombinant plasmid, and lentiviral transduction was performed to inhibit PPA1 expression. The impact on tumor cells was observed, and the expression levels of key proteins in the PI3K/AKT pathway and apoptosis-related factors were detected. &lt;b&gt;Results:&lt;/b&gt; In abnormal immature B lymphocytes from patients with B-ALL, the transcription and expression levels of PPA1 were 3.75 - 14.89 times and 1.25 - 3.79 times those of normal cells, respectively. rPPA1 promoted NALM-6 and HAL-01 cell proliferation, with increased proliferation rates of 29.97% and 20.96% after treatment with 10 μg/ml for 72 h and 48.40% and 58.08% at 20 μg/ml, respectively. PPA1 monoclonal antibody (1:2 000, 1:1 000, 1:500) significantly inhibited proliferation at 19.53%, 46.90%, and 49.42% for NALM-6 cells and 22.29%, 52.41%, and 58.35% for HAL-01 cells, respectively. PPA1 monoclonal antibody (1:2 000, 1:1 000) induced apoptosis, increasing the apoptosis rate of NALM-6 cells from 10.01% to 20.17% and 29.11%, and that of HAL-01 cells from 12.65% to 18.53% and 31.80%. After treatment with the same PPA1 monoclonal antibody dilutions, the proportion of JC-1 monomers significantly increased, reaching 4.08- and 6.49-fold of the control in NALM-6 cells, and 3.99- and 6.42-fold in HAL-01 cells, indicating a decrease in mitochondrial membrane potential, whereas the cell cycle was arrested at the G(0)/G(1) phase. Overexpression of PPA1 for 48 and 72 h increased the proliferation rate of NALM-6 cells by 25.05% and 26.14%, and that of HAL-01 cells by 26.14% and 29.25%, respectively. PPA1 expression inhibition suppressed proliferation, with inhibition rates of 19.77% (48 h) and 28.99% (72 h) for NALM-6 cells, and 20.90% (72 h) for HAL-01 cells. qPCR and Western blot results revealed that PPA1 inhibition reduced the phosphorylation level of the PI3K/AKT pathway and regulated the expression of MDM2, P53, and apoptosis-related factors. &lt;b&gt;Conclusion:&lt;/b&gt; PPA1 is closely associated with the proliferati","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"656-666"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}